Literature DB >> 12796754

Differential effects of antihypertensive agents on electrocardiographic voltage: results from the Appropriate Blood Pressure Control in Diabetes (ABCD) trial.

Edward P Havranek1, Anne Esler, Raymond O Estacio, Philip S Mehler, Robert W Schrier.   

Abstract

BACKGROUND: Serial decline in electrocardiographic voltage in patients with increased left ventricular mass has been associated with a lower risk of cardiovascular events.
METHODS: We studied 468 patients with diabetes mellitus and hypertension in the Appropriate Blood Pressure Control in Diabetes (ABCD) trial. Patients were randomized in a stratified design to receive initial treatment with either enalapril or nisoldipine and to either intensive or moderate treatment goals. We measured an electrocardiographic index for increased left ventricular mass, the adjusted Cornell voltage, serially by treatment group. The association between changes in electrocardiographic voltage and cardiovascular events was defined with Cox proportional hazards analysis.
RESULTS: In 5 years of follow-up, the decline in adjusted Cornell voltage was significantly greater for patients treated with enalapril than for patients treated with nisoldipine (repeated measures analysis of variance P =.002). In the Cox proportional hazards model, treatment assignment (enalapril vs nisoldipine) was the strongest predictor of cardiovascular events, but the presence of coronary disease at baseline, the duration of diabetes mellitus, and change in voltage were also independent predictors of cardiovascular events.
CONCLUSIONS: In the ABCD study, enalapril treatment was associated with a lower risk of myocardial infarction. The reduction in left ventricular mass as reflected by diminished electrocardiographic voltage may explain some, but not all, of the effect of enalapril in this study.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12796754     DOI: 10.1016/S0002-8703(02)94780-0

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  6 in total

1.  Thresholds in the relationship between mortality and left ventricular hypertrophy defined by electrocardiography.

Authors:  Edward P Havranek; Caroline D B Emsermann; Desiree N Froshaug; Frederick A Masoudi; Mori J Krantz; Rebecca Hanratty; Raymond O Estacio; L Miriam Dickinson; John F Steiner
Journal:  J Electrocardiol       Date:  2008-03-14       Impact factor: 1.438

2.  Quality of care and attributable healthcare costs in diabetic hypertensive patients initiated on calcium antagonist therapy.

Authors:  John J Barron; Ibrahim Al-Zakwani; Thomas Iarocci
Journal:  Clin Drug Investig       Date:  2004       Impact factor: 2.859

3.  Screening for left ventricular hypertrophy in patients with type 2 diabetes mellitus in the community.

Authors:  Jithendra B Somaratne; Gillian A Whalley; Katrina K Poppe; Mariska M ter Bals; Gina Wadams; Ann Pearl; Warwick Bagg; Rob N Doughty
Journal:  Cardiovasc Diabetol       Date:  2011-04-14       Impact factor: 9.951

4.  Electrocardiographic left ventricular hypertrophy is not associated with increased in-hospital adverse events in patients with first Non-ST segment elevation myocardial infarction: A single center study.

Authors:  Fatemeh Bakhtiari; Ghiti Davarmoin; Samad Ghaffari; Naser Aslanabadi; Ahmad Separham
Journal:  Caspian J Intern Med       Date:  2019

5.  Blood pressure targets for hypertension in patients with type 2 diabetes.

Authors:  Wilbert S Aronow; Tatyana A Shamliyan
Journal:  Ann Transl Med       Date:  2018-06

6.  Heart rate recovery in exercise test in diabetic patients with and without microalbuminuria.

Authors:  Ali Pourmoghaddas; Adrineh Moghaddasian; Mohammad Garakyaraghi; Negin Nezarat; Ali Mehrabi
Journal:  ARYA Atheroscler       Date:  2013-05
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.